Developing innovative cancer therapies with a focus in USA and China
Who Owns Most Of Athenex Inc (ATNX)? Thu, 23 Nov 2017 20:51:06 +0000 In this article, I will take a quick look at Athenex Inc’s (NASDAQ:ATNX) recent ownership structure – an unconventional investing subject, but an important one. The impact of a company’sRead More...
Athenex to Present at 29th Annual Piper Jaffray Healthcare Conference Wed, 22 Nov 2017 13:00:00 +0000 BUFFALO, N.Y., Nov. 22, 2017-- Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related ...
Athenex, Inc. – Value Analysis (NASDAQ:ATNX) : November 20, 2017 Mon, 20 Nov 2017 18:53:24 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Athenex, Inc. a score of 31. Our analysis is based on comparing Athenex, Inc. with the following peers – Ohr Pharmaceutical, Inc., Omni Bio Pharmaceutical, Inc., OncoMed Pharmaceuticals, Inc. and OrganiGram Holdings Inc (OHRP-US, OMBP-US, OMED-US and OGRMF-US). Investment Outlook Athenex, Inc. has a fundamental score of ... Read more
(Read more...)
Athenex, Inc. breached its 50 day moving average in a Bullish Manner : ATNX-US : November 17, 2017 Fri, 17 Nov 2017 12:25:59 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Athenex, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
Athenex expects to break ground on large pharma factory in Dunkirk in the first quarter of 2018 Thu, 09 Nov 2017 17:40:15 +0000 Athenex expects to break ground on its major pharmaceutical factory in Dunkirk by April 2018, kickstarting one of the most ambitious manufacturing projects in Western New York history. Company executives provided new details on the project during Thursday's conference call with investors. "We're making good progress with the state of New York on our Dunkirk facility," CEO Dr. Johnson Lau told investors.
Athenex reports 3Q loss Thu, 09 Nov 2017 14:12:26 +0000 The Buffalo, New York-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring costs, came to 30 cents per share. The biopharmaceutical company posted revenue of $14 million ...
Athenex, Inc. Announces Third Quarter 2017 Results Thu, 09 Nov 2017 12:00:00 +0000 Encouraging results of 1 st interim analysis of the Oraxol Phase III clinical trial for breast cancer Commencement of the KX-01 ointment Phase III clinical trials for Actinic Keratosis Launched Oxaliplatin ...
What Investors Should Know About Athenex Inc’s (ATNX) Financial Strength Wed, 08 Nov 2017 22:59:09 +0000 Athenex Inc (NASDAQ:ATNX) is a small-cap stock with a market capitalization of USD $927.85M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
Athenex, Inc. to Report Third Quarter 2017 Earnings Results on November 9, 2017 Mon, 30 Oct 2017 12:00:00 +0000 BUFFALO, N.Y., Oct. 30, 2017-- Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 2.67 (median winner: 1.53)
Liquidity: 0.17% (median winner: 1.18%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.